TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

NASDAQ:TGTX

Overview | Financials
Company Name TG Therapeutics, Inc.
Symbol TGTX
Currency USD
Price 16.81
Market Cap 2,597,867,830
Dividend Yield 0%
52-week-range 6.46 - 27.8
Industry Biotechnology
Sector Healthcare
CEO Mr. Michael S. Weiss Esq.
Website https://www.tgtherapeutics.com

An error occurred while fetching data.

About TG Therapeutics, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of

Related Stocks

DocGo Inc. logo

DocGo Inc.

DCGO

3.15 USD

IGM Biosciences, Inc. logo

IGM Biosciences, Inc.

IGMS

8.08 USD

Catalyst Pharmaceuticals, Inc. logo

Catalyst Pharmaceuticals, Inc.

CPRX

15.45 USD

Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp.

AVXL

3.75 USD

Alector, Inc. logo

Alector, Inc.

ALEC

4.7 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

TBPH

8.64 USD

Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

6.04 USD

Financials

Numbers are in millions USD

Numbers are in millions USD